1. Home
  2. LILAK vs NUVB Comparison

LILAK vs NUVB Comparison

Compare LILAK & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Latin America Ltd. Class C

LILAK

Liberty Latin America Ltd. Class C

N/A

Current Price

$9.81

Market Cap

1.7B

ML Signal

N/A

Logo Nuvation Bio Inc.

NUVB

Nuvation Bio Inc.

N/A

Current Price

$4.00

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LILAK
NUVB
Founded
2017
2018
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
LILAK
NUVB
Price
$9.81
$4.00
Analyst Decision
Hold
Strong Buy
Analyst Count
2
13
Target Price
$8.20
★ $12.45
AVG Volume (30 Days)
1.7M
★ 4.9M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
7.55
★ 71.56
EPS
N/A
★ N/A
Revenue
★ $4,442,200,000.00
$62,902,000.00
Revenue This Year
$0.60
$222.99
Revenue Next Year
$3.23
$23.49
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 698.96
52 Week Low
$4.75
$3.98
52 Week High
$10.42
$9.75

Technical Indicators

Market Signals
Indicator
LILAK
NUVB
Relative Strength Index (RSI) 67.41 32.21
Support Level $7.44 N/A
Resistance Level N/A $5.06
Average True Range (ATR) 0.48 0.26
MACD 0.18 -0.02
Stochastic Oscillator 76.79 3.87

Price Performance

Historical Comparison
LILAK
NUVB

About LILAK Liberty Latin America Ltd. Class C

Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: